RhoGDI2 gene and cancer
The RhoGDI2 gene, also known as ARHGDIB, is recognized as an oncogene that encodes a protein functioning as a guanine nucleotide dissociation inhibitor. This protein has a dual role in cancer dynamics: it suppresses the metastatic potential of certain tumors, including bladder cancer, while promoting tumor growth in others, such as breast cancer. RhoGDI2 is expressed in various neoplastic cells, although the mechanisms through which it influences cancer development remain largely unclear.
Understanding the significance of RhoGDI2 is critical, as cancer mortality is often linked to both the growth of the primary tumor and the metastasis to other organs. While surgical removal of primary tumors can be effective, metastasis can lead to recurrence and increased mortality risk. RhoGDI2 has been identified as a potential prognostic marker and therapeutic target due to its ability to inhibit metastasis by interfering with proteins involved in cell signaling, particularly endothelin-1, which is overexpressed in many cancers.
However, studies show mixed results; patients with RhoGDI2-expressing tumors may experience shorter disease-free survival, suggesting that the gene's influence varies depending on the cancer type and location. Ongoing research is essential to fully elucidate RhoGDI2's complex role in cancer progression and its potential applications in treatment strategies.
On this Page
Subject Terms
RhoGDI2 gene and cancer
ALSO KNOWN AS: Guanine nucleotide dissociation inhibitor (GDI), ARHGDIB gene
DEFINITION: RhoGDI2, also known as ARHGDIB, is an oncogene whose product is a guanine nucleotide dissociation inhibitor (GDI) called RhoGDI2. RhoGDI2 suppresses the metastatic potential of several types of tumors, including those of the bladder, yet promotes tumors in breast tissues. RhoGDI2 is expressed within a variety of neoplastic cells. The mechanisms of RhoGDI2's effects on cancer development are unknown and remain an area of study.
Significance: Mortality associated with cancer can be the result of two separate but interrelated processes: growth of the primary tumor and metastasis of the growth to distal sites, potentially any organ in the body, which may result in damage to that organ. Removal of the primary tumor by surgery may eliminate one growth, but if metastasis has taken place, the tumor may recur at other sites, potentially proving fatal. Elimination of metastatic growth sites has been addressed using chemotherapy and radiation therapy, methods of treatment that may have significant side effects.
The discovery of RhoGDI2 and its role in tumor progression presents a potential prognostic marker and a possible means of limiting metastasis. The gene product has been found to suppress metastasis in certain cancers, apparently by interfering with the function of endothelin, a member of a protein family involved in cell signaling and cell dissemination from primary tumors.
Endothelin-1 was found to be overexpressed in several forms of cancer, but particularly in ovarian cancers, and appears to play an important role in their development. Because it appears to be an important factor in the metastasis of these neoplasms, the use of the RhoGDI2 gene product has been studied for its potential to suppress metastasis, providing a reassuring means to control and treat these diseases.
Other studies, however, have found that patients with RhoGDI2-expressing tumors had significantly shorter disease-free and metastasis-free survival than patients who did not have RhoGDI2-expressing tumors. This suggests that RhoGDI2's role in cancer metastasis may be influenced by the type of cancer tissue and the organ in which the primary tumor is located. This underscores the need for further studies to clarify RhoGDI2's role in tumorigenesis and cancer progression.
In the mid-2020s, medical researchers continued studying RhoGDI2 to better understand its tumor-suppressing and tumor-promoting qualities. Studies continued to indicate that RhoGDI2 played a role in treating bladder cancer. However, the gene also appeared to promote the spread of other cancers, such as colorectal cancer. Because of its unique relationship with cancer cells, more studies of RhoGDI2 are necessary.
Bibliography
Griner, Erin M., and Dan Theodorescu. "The Faces and Friends of RhoGDI2." Cancer and Metastasis Reviews, vol. 31.3–4, 2012, pp. 519–28.
Harding, Michael A., and Dan Theodorescu. "RhoGDI Signaling Provides Targets for Cancer Therapy." European Journal of Cancer, vol. 46.7, 2010, pp. 1252–59.
Moon, Hyeong-Gon, et al. "Up-Regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications." Cancer Research and Treatment, vol. 42, no. 3, 2010, pp. 151-156.
Niu, Huiyan, et al. "Expression Profile of RhoGDI2 in Lung Cancers and Role of RhoGDI2 in Lung Cancer Metastasis." Oncology Reports, vol. 24, no. 2, 2010, pp. 465-471.
Qayyum, T, et al. "The Interrelationships between Src, Cav-1 and RhoGD12 in Transitional Cell Carcinoma of the Bladder." British Journal of Cancer, vol. 106, no. 6, 2012, pp. 1187-1195, doi.org/10.1038/bjc.2012.52. Accessed 1 July 2024.
Tapper, J., et al. "Changes in Gene Expression during Progression of Ovarian Carcinoma." Cancer Genetics and Cytogenetics, vol. 128.1, 2001, pp. 1–6.
Tripathi, Mudrika, et al. "The Dual Function of RhoGDI2 in Immunity and Cancer." International Journal of Molecular Sciences, vol. 24, no. 4, 2023, doi.org/10.3390/ijms24044015. Accessed 1 July 2024.
Zhang, Yaqin, and Baolin Zhang. "D4-GDI, a Rho GTPase Regulator, Promotes Breast Cancer Cell Invasiveness." Cancer Research, vol. 66, no. 11, 2006, pp. 5592-5598.